Mitoxantrone
Mitoxantrone is a synthetic anthracenedione antineoplastic agent used in veterinary oncology for a variety of neoplastic diseases in dogs and cats. **Key Clinical Applications:** * **Lymphoma:** Often used as a rescue agent when first-line protocols (like CHOP) fail. * **Carcinomas:** Efficacious against transitional cell carcinoma (TCC), squamous cell carcinoma, renal adenocarcinoma, and thyroid carcinomas. * **Sarcomas:** Used for fibrosarcoma, hemangiopericytoma, and mammary adenocarcinoma. **Clinical Pearls:** * Structurally related to anthracyclines (like doxorubicin) but lacks the amino sugar moiety, which significantly reduces the generation of free radicals. This makes mitoxantrone **substantially less cardiotoxic** than doxorubicin. * Because its renal clearance is minimal (~10%), it is a much safer alternative to doxorubicin for cats with pre-existing renal insufficiency. * Often colloquially referred to as "blue thunder" in veterinary oncology due to its dark blue color and potent efficacy.
Mecanismo: Mitoxantrone exerts its cytotoxic effects through multiple mechanisms: * **DNA Intercalation:** It inserts itself between DNA base pairs, causing structural distortion. * **Electrostatic Interaction:** Nonintercalative binding to DNA further stabilizes the drug-DNA complex. * **Topoisomerase II Inhibition:** **(Pharmacological addition)** It inhibits the enzyme Topoisomerase II, preventing the religation of DNA strands and leading to double-strand DNA breaks. * **Synthesis Inhibition:** Ultimately inhibits both DNA and RNA synthesis. While it is not strictly cell-cycle phase specific, it demonstrates the highest activity during the **S phase** (DNA synthesis phase) of the cell cycle.
Dosificación por especie
- Soft-tissue sarcomas · 6-6.5 mg/m2 IV given every 3-4 weeks for 4-6 treatments · IV · every 3-4 weeks · 4-6 treatments
- Effective dose (general) · 6.5 mg/m2 IV every 2-3 weeks · IV · every 2-3 weeks
- Single rescue agent for lymphoma · 6-6.5 mg/m2 IV every 3 weeks · IV · every 3 weeks
- Transitional cell carcinoma · 5 mg/m2 IV every 21 days with piroxicam (0.3 mg/kg PO once daily) · IV · every 21 days
- Lymphoma, squamous cell carcinoma, transitional cell carcinoma, mammary gland tumors, etc. · 6 mg/m2 IV every 2-3 weeks · IV · every 2-3 weeks
- Single rescue agent for lymphoma · 5.5-6 mg/m2 IV every 3 weeks · IV · every 3 weeks
- Rescue agent for canine lymphoma · 6 mg/m2 IV every 2-3 weeks · IV · every 2-3 weeks · Check CBC on day 7 after treatment and the protocol can be repeated on day 14 or 21 if the dog attains complete or partial response. Combining with DTIC (dacarbazine) may improve response rate.
- Transitional cell carcinoma after laser ablation of the primary tumor · 5 mg/m2 IV every 3 weeks for 4 treatments · IV · every 3 weeks · 4 treatments · Piroxicam was given at a dosage of 0.3 mg/kg PO once daily for the remaining life of the dog.
Las dosis son una referencia clínica para veterinarios colegiados. Confirme siempre con la ficha técnica vigente y el paciente individual.
Vías de administración
Contraindicaciones
- Severe pre-existing myelosuppression
- Concurrent active infection
- Significantly impaired cardiac function
- Patients with prior extensive cytotoxic drug or radiation exposure (relative)
- Pregnancy (FDA Category D) and nursing mothers
- Pre-existing myelosuppression
- Concurrent infection
- Hepatic disease
- Impaired cardiac function
Efectos adversos
- Dose-dependent GI distress (vomiting, anorexia, diarrhea)
- Bone marrow depression (neutropenia, sepsis; nadir typically around day 10)
- Non-regenerative anemia
- Lethargy
- Seizures (specifically noted in cats)
- Blue-green discoloration of urine and sclera (benign)
- Tissue necrosis or phlebitis (if extravasated, though less severe than doxorubicin)
- Rarely: conjunctivitis, jaundice, renal failure, allergic reactions, thrombocytopenia
- Gastrointestinal signs (vomiting, anorexia, diarrhoea)
- Bone marrow depression (WBC nadir generally at 10 days)
- Seizure activity (reported in cats)
- Blue discoloration of urine and sclera (very rare)
- Acute renal failure (anecdotal in cats)
Interacciones farmacológicas
- Doxorubicin, Daunorubicin, or Radiation Therapy · Cardiotoxicity risks may be enhanced in patients that have previously received these therapies to the mediastinum.
- Immunosuppressant Drugs (e.g., azathioprine, cyclophosphamide, corticosteroids) · Concurrent use may significantly increase the risk of severe infection.
- Myelosuppressive Drugs (e.g., chloramphenicol, flucytosine, amphotericin B, colchicine) · Additive bone marrow depression; use with extreme caution.
- Live Vaccines · Increased risk of vaccine-induced infection; should be used with extreme caution or avoided during therapy.
- Myelosuppressive agents · Increased risk of severe bone marrow depression · major
- Immunosuppressive agents · Increased risk of severe immunosuppression and infection · major
- Heparin · Chemically incompatible · major
Monitorización
- CBC with differential and platelets (especially around day 7-10 to check for nadir)
- Tumor measurements/efficacy
- Chest radiographs, ECG, or other cardiac function tests (if cardiac symptomatology is present)
- Liver function tests (if jaundice or clinical signs of hepatotoxicity occur)
- Serum uric acid levels (for susceptible patients)
- Complete Blood Count (CBC), especially WBC count around day 10 post-administration
- Gastrointestinal signs (vomiting, diarrhoea, appetite)
- Renal parameters (especially in cats)
- Hepatic function
- Cardiac function (echocardiogram) if pre-existing disease exists
Sobredosis
Due to the narrow therapeutic index and potential for serious toxicity (profound myelosuppression, severe GI mucosal damage, sepsis), dosage determinations must be made with extreme care. Overdose management is primarily supportive, focusing on aggressive fluid therapy, broad-spectrum antibiotics to manage sepsis secondary to neutropenia, and potentially the use of recombinant granulocyte-colony stimulating factors (G-CSF) to accelerate bone marrow recovery.
La referencia de fármacos de VetSheet está destinada a veterinarios colegiados como apoyo a la decisión clínica, no sustituye el juicio profesional ni la ficha técnica vigente del fabricante.